








Takeda Oncology Pipeline

Our research and development efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers by leveraging modalities best suited to make a difference in the treatment of these diseases. Our core modalities include antibody-drug conjugates (ADCs), complex biologics, small molecules and gamma delta T cell therapies.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

INVESTIGATIONAL THERAPY	MODALITY	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
Brentuximab vedotin*	ADC	<i>Newly diagnosed Hodgkin lymphoma (EU)</i>	Filed 	Pfizer and Takeda fund joint development costs on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs. Takeda has commercialization rights for the treatment outside of U.S. and Canada.
Elritercept (TAK-226)*	Complex biologic	<i>Second-line anemia-associated myelodysplastic syndromes</i>	Phase 3 	Takeda has development and commercialization rights for the treatment worldwide outside of mainland China, Hong Kong and Macau. Activin A and B inhibitor (injection)
		<i>Anemia-associated myelofibrosis</i>	Phase 2 	
Mirvetuximab soravtansine-gynx (TAK-853)	ADC	<i>Folate receptor alpha (FRA)-positive platinum-sensitive ovarian cancer (JP)</i>	Phase 3 	Takeda has development and commercialization rights for the treatment in Japan.
		<i>Folate receptor alpha (FRA)-positive platinum-resistant ovarian cancer (JP)</i>	Phase 1/2 	
Rusfertide (TAK-121)	Small molecule	<i>Polycythemia vera (USA)</i>	Phase 3 	Collaboration with Protagonist Therapeutics. Protagonist is responsible for development in the U.S. through the completion of the Phase 3 VERIFY trial. Takeda has rights for ex-U.S. development and is responsible for leading global regulatory and commercialization activities. Hepcidin mimetic peptide (injection)
TAK-012	Gamma delta T cell therapy	<i>Acute myeloid leukemia</i>	Phase 1/2a 	

*Marketed products have received approval in one or more jurisdictions.

*Treatments have one or more clinical trials in active recruitment.

All programs have global development rights unless otherwise noted.

GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets.



Learn more at [TakedaOncology.com](https://www.takedaoncology.com)

©2025 Takeda Pharmaceuticals U.S.A., Inc



ONCOLOGY